“
TL;DR
The authors conclude that nanoparticles generally demonstrate improved uptake, sustained retention, enhanced cytotoxicity, and better antitumor effects compared to conventional treatments, though clinical translation remains limited.
Nanoscale Advances · 11 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors conclude that nanoparticles generally demonstrate improved uptake, sustained retention, enhanced cytotoxicity, and better antitumor effects compared to conventional treatments, though clinical translation remains limited.
This narrative review synthesizes preclinical evidence on nanoparticle-based drug delivery systems for retinoblastoma, the most common intraocular malignancy in children. The authors describe how current treatments—surgery, radiotherapy, and chemotherapy—are limited by systemic side effects and off-target drug distribution to non-cancerous cells. Nanoparticulate systems are reported to offer targeted delivery, enhanced penetration and retention effects, increased bioavailability, and improved toxicity profiles. However, the authors note that clinical translation of these preclinical findings has not received adequate attention. The review identifies key challenges in translating nanoparticle carriers to clinical use and highlights prospects for improving diagnosis, chemotherapy safety, and efficacy in retinoblastoma patients.